iTeos Therapeutics, Inc. (NASDAQ:ITOS)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $27.01, but opened at $26.20. iTeos Therapeutics shares last traded at $24.27, with a volume of 5,331 shares traded.
A number of analysts have recently weighed in on ITOS shares. SVB Leerink upped their price target on shares of iTeos Therapeutics from $37.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wedbush upped their price target on shares of iTeos Therapeutics from $46.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, March 25th. Finally, Zacks Investment Research raised shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. iTeos Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $49.40.
The firm’s 50 day moving average is $35.75 and its 200 day moving average is $31.12.
In related news, major shareholder Bioventures 2014 L.P. Mpm sold 5,783 shares of the company’s stock in a transaction that occurred on Wednesday, April 7th. The shares were sold at an average price of $32.55, for a total value of $188,236.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Several institutional investors and hedge funds have recently made changes to their positions in ITOS. Penserra Capital Management LLC acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth $27,000. Morgan Stanley acquired a new position in shares of iTeos Therapeutics during the 3rd quarter worth $59,000. Strs Ohio acquired a new position in shares of iTeos Therapeutics during the 3rd quarter worth $66,000. JPMorgan Chase & Co. bought a new stake in iTeos Therapeutics in the 3rd quarter valued at $96,000. Finally, Citigroup Inc. boosted its holdings in iTeos Therapeutics by 544.1% in the 4th quarter. Citigroup Inc. now owns 3,304 shares of the company’s stock valued at $112,000 after purchasing an additional 2,791 shares during the period. Institutional investors own 71.07% of the company’s stock.
About iTeos Therapeutics (NASDAQ:ITOS)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial.
Featured Article: What are economic reports?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.